HIGH RISK MYELODYSPLASTIC SYNDROME

This study is testing a combination of two drugs to treat acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The first part aims to find the safest and most effective dose of a packaged chemotherapy (CPX-351) when given with a targeted pill (quizartinib). …

This study is testing whether a drug called dexrazoxane can protect the heart from damage caused by powerful chemotherapy used to treat aggressive blood cancers like acute myeloid leukemia. It will enroll 100 patients with these cancers who are receiving a specific combination of…

This study is testing a combination of five drugs to treat adults newly diagnosed with specific, aggressive forms of blood cancer. The goal is to see if this combination is safe and effective at putting the cancer into remission. The treatment involves chemotherapy and a targeted…

This study is testing whether adding a newer drug called venetoclax to a standard, strong chemotherapy regimen works better for adults with acute myeloid leukemia (AML). The goal is to see if this combination is safe, find the best dose, and measure how well it controls the cance…

This early-stage study is testing whether adding metal-detoxifying drugs to standard chemotherapy can help control acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to see if lowering metal levels in the blood and bone marrow improves treatment res…

This trial is testing whether adding a newer targeted drug (quizartinib) to a standard three-drug chemotherapy cocktail works better for controlling aggressive blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It is for adults (18-65 fo…

This is the first study in people testing a new drug called CBX-250 for several types of advanced blood cancers that have come back or stopped responding to standard treatments. The main goal is to find a safe dose and see how well the body handles the drug, which is given as an …